Subcutaneous injection ofthe potent, nonselective opioid antagonist diprenorphine inhibits the vasopressin response to acute hypovolemia. To determine if this inhibition is due to antagonism of opioid receptors in brain pathways that mediate volume control, we determined the vasopressin response to different stimuli when diprenorphine or other opiates were injected into the cerebral ventricles, the nucleus tractus solitarius (NTS), or the lateral parabrachial nucleus (PBN) of rats. We found that the vasopressin response to hypovolemia was inhibited by injection of diprenorphine into the cerebral ventricles at a dose too low to be effective when given subcutaneously. This response also was inhibited when a 20-fold lower dose of diprenorphine was injected into the PBN but not when it was injected into the NTS. The inhibitory effect of diprenorphine in the PBN was not attributable to a decrease in osmotic or hypovolemic stimulation and did not occur with osmotic or hypotensive stimuli. Injecting the PBN with equimolar doses ofthe A antagonist naloxone, the a antagonist ICI-154,129 or the K-1 agonist U-50,488H had no effect on basal or volume-stimulated vasopressin. We conclude that the inhibition of vasopressin by diprenorphine is due partially to action at a novel class of opioid receptors that transmit volume stimuli through the PBN. (J.
Introduction
Although secretion ofthe antidiuretic hormone, arginine vasopressin, is regulated primarily by blood osmolality, it can also be stimulated by moderately large reductions in blood volume or pressure (1) . These hemodynamic influences appear to be relatively unimportant under physiologic conditions but they may be responsible for the disturbances of vasopressin secretion and water balance in many clinical disorders such as heart failure or cirrhosis ofthe liver (2). Some ofthe neural pathways that mediate these hemodynamic influences have been elucidated (3-5) but relatively little is known about their neurochemistry.
Recently, we found that subcutaneous injection of diprenorphine, a potent nonselective opioid antagonist (6) , almost completely eliminates the plasma vasopressin response to an acute hypovolemic stimulus in conscious rats (7) . The drug did not affect basal, unstimulated levels of plasma vasopressin and had little or no inhibitory effect on the hormonal response to osmotic or hypotensive stimuli. This selectivity suggested that diprenorphine inhibits the vasopressin response to acute hypovolemia by antagonizing opioidergic neurotransmission at one or more sites along the afferent pathways that transmit signals from peripheral volume receptors to the neurohypophysis. To test this hypothesis, we have performed a series of experiments to determine if the vasopressin response to hypovolemic, osmotic, or hypotensive stimuli is inhibited by injecting small doses of diprenorphine into the cerebral ventricles, the nucleus tractus solitarius (NTS),' or the lateral parabrachial nucleus (PBN). These two nuclei were selected as likely candidates for the site ofthe inhibitory action ofdiprenorphine because they both contain large numbers of opioidergic peptides and/or receptors ( 8, 9 ) and appear to play an important role in the hemodynamic control of vasopressin secretion (10) (11) (12) (13) (14) (15) (16) . To clarify the mechanism of action of diprenorphine, we also determined the effects ofinjecting the PBN with naloxone, a prototype ,u antagonist, ICI-154,129, a selective S antagonist ( 17), or U-50,488H, a potent Kagonist ( 18, 19) .
Methods

Animals
Male Sprague-Dawley rats (300-400 g, Sasco, Omaha, NE) were maintained on standard rat laboratory diet and tap water in a temperature-, humidity-, and light-controlled vivarium for 7 d (lights on from 6 a.m. to 6 p.m.). Only those that gained weight normally or showed no evidence of illness were studied. Rats were allowed to eat and drink ad libitum until the start of experiment. Drugs Diprenorphine was supplied by the National Institute on Drug Abuse (Bethesda, MD). It was stored at room temperature until the day ofthe experiment, when it was dissolved in physiologic saline at concentrations of 0.22 or 2.2 liM for subcutaneous (s.c.) injection; at 8.8 or 88 MuM for injection into the cerebral ventricle (i.c.v.); at 45, 83, or 165 AM for microinjection into specific nuclei. Naloxone (Endo Laboratories, Wilmington, DE) was stored at room temperature until the day of the microinjection experiment when it was dissolved in physiologic saline at a concentration of 83 MM. ICI-1 54,129 (a gift from Dr. M. Rance, Imperial Chemical Industries PLC, Cheshire, UK) was stored at 4VC until the day ofthe microinjection experiment when it was dissolved in physiologic saline at a concentration of 83 ,M. U-50,488H (a gift from Dr. P. VonVoigtlander, The Upjohn Co., Kalamazoo, MI) was stored at 4VC until the day ofthe experiment when it was dissolved in physiologic saline at a concentration of 100 ,uM.
Basic experimental protocol
Vasopressin stimulation. Three kinds of stimuli were used: (a) Acute isotonic hypovolemia was induced (20) by giving an intraperitoneal (i.p.) injection of 20 ml/kg body weight of normal saline containing 20% (wt/vol) polyethylene glycol (PEG) 3350 (Sigma Chemical Co., St. Louis, MO). (b) Acute, normovolemic hyperosmolality was induced (20) by giving an i.p. injection of 20 ml/kg body weight of hypertonic (600 mmol/kg) saline. (c) Acute hypotension was induced (7) by giving a s.c. injection of 1 ml/kg body weight of 0.1% (wt/vol) sodium nitroprusside (Sigma Chemical Co.) in normal saline.
Opioid administration. Opioids were injected three ways. Injections s.c. (1 ml/kg) were given at the back of the neck with a 20-gauge needle. Injections i.c.v. were given via chronically implanted cannulae. For this purpose, rats were anesthetized with pentobarbital, 60 mg/kg i.p., and ketamine HCI, 21 mg/ kg intramuscular (i.m.), then fixed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) with the incisor bar 5 mm above the intraaural line. After incising the scalp in the midline, a fine hole was drilled 0.3 mm posterior and 1.5 mm to the right of the bregma and a sterile 27-gauge stainless needle was inserted 4.5 mm below the surface ofthe skull into the right lateral ventricle. After the cannula was secured to the skull with acrylic cement, the scalp was closed with skin clips and the animals were placed in individual cages for 7 d and supplied with drinking water containing an oral antibiotic, erythromycin. Only those rats which regained their preoperative weight and showed no evidence of infection were studied. On the day of the experiment, a polyethylene tube (PE-20) containing normal saline with or without the drug was connected to a 10-Ml Hamilton syringe and 25 til/kg ofsolution was injected over a period of2 min. 30 min later, the rats were killed by decapitation and their trunk blood was collected for subsequent analysis. To verify positioning, the i.c.v. cannulae were injected with the same volume of India ink immediately after decapitation ofthe animal, and the brain was removed, hand-sectioned, and inspected. Ifthe ink was not clearly visible outlining at least one lateral ventricle, the data from that rat were excluded from analysis.
Microinjections into specific brain nuclei were given acutely under general anesthesia. For this purpose, a-chloralose, 75 mg/kg i.p., was used because this drug has been shown to interfere minimally, if at all, with cardiovascular reflexes (21 ) and, in our preliminary experiments, it did not affect either basal or volume-stimulated levels of plasma vasopressin (not shown). For injections ofthe NTS, rats were placed in a stereotaxic frame with the incisor bar 13 mm below the interaural line, and the dorsal surface of the medulla was exposed by removal of the muscle insertions on the occipital bone and the atlanto-occipital membrane. The obex was identified through a stereoscopic microscope and the pipet was lowered to the calamus scriptorius, which served as the rostral-caudal (AP) and medio-lateral (ML) zero 
Results
Experiment I. In rats with acute hypovolemia induced by i.p. injection ofPEG (groups 2-6), the resultant increase in plasma vasopressin was significantly less in the group in which 2.2 nmol/kg of diprenorphine was injected i.c.v. (Fig. 1) . Injection i.c.v. of a 10-fold lower dose of the drug also appeared to slightly inhibit the rise in vasopressin but the value did not differ significantly from that in the untreated, hypovolemic rats (group 2). The inhibitory effect ofthe i.c.v. injection ofdiprenorphine was not associated with any decrease in plasma sodium or the degree of hypovolemia as indicated by the rise in hematocrit. Indeed, plasma sodium was actually slightly higher in the rats (group 4) in which plasma vasopressin was decreased by i.c.v. injection ofdiprenorphine. When injected s.c., neither dose of diprenorphine had any effect on the plasma vasopressin response to acute hypovolemia. Compared to the euvolemic or hypovolemic controls (group 1 or 2), plasma sodium was slightly higher in the rats injected s.c. with the lower dose of diprenorphine (group 5) but not in those receiving the higher dose (group 6). In the five groups of rats with PEG-induced hypovolemia, plasma osmolality was also higher (range 303-305 mmol/kg) than in the normovolemic, shamtreated controls (299 mmol/kg, group 1) but this difference was due largely to a slightly higher plasma urea (range 8.6-10.1 mM in PEG treated rats vs. 7.4 mM in control rats). Plasma glucose was similar in all six groups (range 7.7-8.1 mM).
Experiment II. In normovolemic control rats injected i.p. with normal saline (groups 1 and 2), basal plasma vasopressin, hematocrit, and plasma sodium did not differ in the groups in which diprenorphine or saline was microinjected into the NTS (Fig. 2 ). In the rats injected i.p. with PEG (groups 3 and 4), plasma vasopressin and hematocrit were significantly higher than in the controls (groups 1 and 2) and neither variable differed in the groups given diprenorphine or saline vehicle into the NTS. Plasma osmolality and urea were again slightly higher in the PEG-treated groups than in the controls (305±3 and 307±2 vs. 297±1 and 300±2 mmol/kg; 9.0+0.9 and 10.1±1.3 vs. 6.5±0.4 and 7.6±1.1 mmol/ kg) but the values did not differ in the groups given saline or diprenorphine in the NTS. Plasma sodium was slightly higher in group 2 than in group 3 but it did not differ in the sham and diprenorphine-treated groups. Similar negative results were obtained in a repeat experiment. In both studies, the magnitude ofthe vasopressin responses in the sham and drug-treated hypovolemic groups were almost twofold greater than in any of the other experiments, even though plasma sodium and the reduction in blood volume were about the same. Inspection ofbrain slices confirmed that the injectate containing the methylene blue dye was concentrated in the intermediate portion of the NTS (Fig. 3) .
Experiment III. In normovolemic control rats injected i.p. with normal saline (groups 1 and 2), basal plasma vasopressin, hematocrit, and plasma sodium did not differ between the groups in which saline or 0.1 1 nmol/kg of diprenorphine was injected into the PBN (Fig. 4) . However, in the rats in which hypovolemia was induced by i.p. injection of PEG (groups 3 and 4), the resultant increase in plasma vasopressin was almost 50% less in the group in which diprenorphine was microinjected into the PBN. This inhibition was not associated with a demonstrable decrease in plasma sodium or the level ofhypovolemia as indicated by the rise in hematocrit. As in the other experiments, the rats injected with PEG had slightly higher levels of plasma osmolality (304±2 and 304±1 vs. 300±1 and 300±0 mmol/kg) and urea (8.4±0. 5 Inspection of effect was still apparent, at least at the higher dose. As in the )n of diprenorother experiments, the inhibitory effects of diprenorphine were to acute hyponot associated with any differences in hematocrit or plasma the methylene sodium. Plasma osmolality and urea were again slightly higher iart of the PBN in the four PEG-treated groups and neither was affected by in a repeat exdiprenorphine treatment. As in the other PBN microinjection rug-treated rats experiment, mean plasma vasopressin in the rats receiving the -he microinjecmaximally effective inhibitory dose of diprenorphine (group 4) the other, both appeared to be higher than in the normovolemic controls I. Their plasma (group 1) but the difference was not statistically significant. ,he range in the Two rats in the group injected with 0.1 nmol/kg of diprenorrolemic groups phine were excluded from analysis because the microinjection missed the PBN on one side. Their plasma AVP levels (49 and uced hypovole-38 pM) were within the range found in the sham-treated hypo-(asopressin was volemic controls (group 3). diprenorphine Experiment V. In rats injected i.p. with hypertonic (600 (Fig. 6 ). In the mmol/kg) saline (groups 2 and 3), plasma vasopressin as well diprenorphine as plasma osmolality and plasma sodium were higher than in ibited but some the controls (group 1) injected i.p. with isotonic saline (Fig. 7) . The increases in plasma vasopressin as well as osmolality and sodium were similar in the groups in which saline or 0.11 nmol/kg of diprenorphine were microinjected into the PBN. Hematocrit as well as plasma urea and glucose were similar in * all three groups. Experiment VI. In rats with acute hypotension induced by s.c. injection ofsodium nitroprusside (groups 2 and 3), plasma vasopressin as well as plasma glucose were higher than in the normotensive controls (group 1) (Fig. 8) . The increases in _ * plasma vasopressin and glucose induced by hypotension did _ not differ in the groups in which saline or 0.1 1 nmol/kg of diprenorphine were injected into the PBN. Plasma sodium and hematocrit were similar in all three groups. Experiment VIL In the rats with PEG-induced hypovolemia, the resultant increase in plasma vasopressin appeared to be slightly greater in those given PBN injections of naloxone (group 3) than ICI-154,129 (group 4) or saline vehicle (group 2) (Fig. 9) . However, the values in group 3 were not signifi-** cantly different from those in the sham-treated hypovolemic controls. The failure of these antagonists to alter the vasopressin response to hypovolemia was not attributable to any coun--_ tervailing differences in plasma sodium or blood volume as indicated by the hematocrit. There were also no differences in indplasma osmolality, urea, or glucose among the PEG-treated groups (not shown). Experiment VIII. In normovolemic control rats injected I_ i.p. with normal saline (groups 1 and 2), basal plasma vasopressin, hematocrit, and plasma sodium were within normal limits and did not differ in those in which the PBN was injected with saline or 0. 14 nmol/kg ofU-50,488H (Fig. 10 ). In the rats with PEG induced hypovolemia (groups 3 and 4), plasma vasopressin as well as hematocrit were higher than in the normovolemic controls and neither variable differed in the groups in which saline or U-50,488H were injected into the PBN. The 3 4
failure ofU-50,488H to affect plasma vasopressin was not asso- 6 6 ciated with any countervailing difference in plasma sodium.
PEG PEG The groups with PEG induced hypovolemia had slightly higher sal DPN levels of plasma osmolality (303±1 and 304±2 vs. 297±2 and 297±2 mmol/kg) and urea (7.9±0.6 and 8.5±0. 
Discussion
The results of this study support our hypothesis that diprenorphine inhibits the plasma vasopressin response to an acute hypovolemic stimulus by acting, at least in part, at a site along the neuronal pathway that transmits signals from the peripheral volume receptors to the neurohypophysis. This concept is supported by the fact that the inhibitory effect of diprenorphine was at least 10-fold greater when the drug was given i.c.v. instead of s.c. (Fig. 1) and it was almost 200-fold greater when it was microinjected bilaterally into the lateral PBN (Figs. 4 and  6 ). The latter effect was unlikely to be due to leakage of the injection into cerebrospinal fluid and action at a distant site because the dose which produced inhibition when injected into the PBN was 1/20 of that required to have the same effect when it was injected directly into the ventricular system. The inhibition of vasopressin also cannot be attributed to a reduction in the intensity of hypovolemic or osmotic stimulation since neither hematocrit, plasma sodium, osmolality, urea, nor glucose were decreased by the diprenorphine treatment. Because of the potential confounding effects of the additional surgical instrumentation, we did not attempt to measure arterial pressure in the i.c.v. or microinjected rats. However, the inhibitory effect of diprenorphine is probably not due to a rise in blood pressure because the drug does not have this effect when given s.c. even in very large doses (7). It also cannot be attributed to activation of some nonspecific inhibitory input to the neurohypophysis because injections of the drug into the PBN had no effect on the vasopressin response to osmotic or hypotensive stimuli (Figs. 7 and 8 ). We conclude, therefore, that the inhibition of volume induced vasopressin secretion by diprenorphine is achieved, at least in part, by a direct action of the drug on opioidergic receptors located in or near the lateral PBN. These observations are consistent with previous reports that the lateral PBN contains receptors for diprenorphine (25) and is a link in the reflex pathway from peripheral baroreceptors to the hypothalamus (4). Indeed, it has been shown recently that this nucleus not only receives neuronal projections from the NTS (26) (27) (28) (29) , the first brainstem synapse for vagal and glossopharyngeal afferents from peripheral baroreceptors (30) , but it also sends projections to the paraventricular and median preoptic nuclei, as well as to the perinuclear zone surrounding the supraoptic nucleus (31) (32) (33) , all of which are known to be involved in the regulation of vasopressin secretion. Consistent with this anatomic data, there is also functional evidence that the PBN is involved in the regulation of vasopressin secretion ( 1 3-16) as well as cardiovascular regulation (34). Hence, the results of the present study provide new, pharmacologic evidence to support a large body of prior anatomical and functional data that the PBN is a link in the neuronal pathway that subserves the hemodynamic control of vaso- pressin secretion. Our finding that injecting the PBN with diprenorphine inhibits the vasopressin response to acute hypovolemia (Figs. 4 and 6 ) but not to acute hypotension (Fig.  8) is noteworthy because it provides clear evidence that, at this level, the pathways conveying the two stimuli remain largely if not totally distinct. This differentiation is probably neurochemical as well as anatomic because the AVP response to a hypotensive stimulus is also unaffected when large doses of diprenorphine are given systemically (7) and is potentiated rather than diminished by electrolytic lesioning of the lateral PBN ( 15) . Taken together, these three findings suggest that the AVP response to acute hypotension is mediated by nonopioidergic pathways located in other areas, whereas the lateral PBN contains opioid-mediated, stimulatory afferents from the low pressure, volume control system as well as inhibitory projections of uncertain character and origin. The These studies do not exclude the possibility that diprenorphine acts at additional sites to inhibit the vasopressin response * to hypovolemia. Even at maximally effective inhibitory doses of diprenorphine, plasma vasopressin in the hypovolemic rats was always slightly higher than in the euvolemic controls (Figs.  4 and 6 ). Although these differences were not statistically significant and could have been due simply to slight inadequacies in the size or placement ofthe injections, they may also signify the existence ofalternative neural or humoral paths for the volume control of vasopressin secretion. If these additional pathways exist, at least some ofthem may also be diprenorphine sensitive since the maximum vasopressin suppression achieved when the drug was given systemically (7) appears to be greater (about 90%) than when it was given i.c.v. (70%) or into the PBN (60%). The apparently lesser inhibition observed when diprenorphine was injected into the PBN was not overcome by doubling the dose of the drug (Fig. 6) pressin secretion (Fig. 10) . We postulate, therefore, that the inhibitory effect of diprenorphine in the PBN is achieved by blocking endogenous stimulation of some other class of opioid receptor, most likely the recently recognized K-2 or K-3 subtypes ( 19) . This hypothesis is consistent with other evidence that the PBN is richly innervated with opioidergic neurons (9, 37), some ofwhich originates in the NTS (27) and that it also binds large amounts oftritiated diprenorphine which cannot be completely displaced with a combination of u, 6, and K-1 ligands (38) . It is also consistent with the lack of a stimulatory or inhibitory effect of the K-1 agonist, U-50,488H (Fig. 10 ) since this drug is reported to have a relatively low affinity for K-2 and K-3 receptors ( 19) . The role ofthe other, more "conventional" diprenorphine binding sites in the PBN is unknown. However, the tendency ofnaloxone to enhance the AVP response to hypovolemia (7) (Fig. 9 ) raises the possibility that some ,u-type receptors subserve inhibitory pathways in the lateral PBN and, possibly, elsewhere. If so, the failure of microinjected diprenorphine to completely suppress plasma AVP in hypovolemic rats (Fig. 6 ) could be due to simultaneous blockade of this inhibitory pathway. that, at high doses, diprenorphine acts as a v perhaps like naloxone (Fig. 9 ), begins to antag tory effect of some other endogenous opioid are other diprenorphine sensitive sites in the sy ates hypovolemic stimulation of vasopressin, ti monstrable in the intermediate part of the N1 though this region contains a relatively high co opioids (9) . However, these results do not nece site of action in the NTS because the injection enough to cover the entire nucleus. Moreove reasons, microinjections in this area consistent vasopressin response to the hypovolemic stinr lack of effect ofdiprenorphine also could have I to the increased intensity ofthe stimulus. Neve exploration of other areas like the ventrome medulla, the subfornical organ and the medial I would be worthwhile since they also receive p the NTS (39) (40) (41) and contain relatively high ca opioid peptides and receptors (8, 9 ). *
